RxDoctor Payments DataLook up a doctor →

Amit Shah, MD

Internal Medicine · Indian Land, SCNPI 1740288323

Payments from drug & device makers

$1,374,278in general payments, 2019–2025

Across 532 payments — averaging $2583.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$484K
  • Regeneron$301K
  • Novartis$148K
  • GSK$124K
  • AstraZeneca$120K
  • Kowa Research Institute, Inc.$47K
  • plus $151K from 37 others

What the payments were for

  • Travel & lodging$3,37649%
  • Food & beverage$3,56151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,374,278 in reported general payments places this provider in the 95th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$497,425
Medicare patients
776
Services billed
5,849

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban43$41,321
TrulicityDulaglutide21$29,341
OzempicSemaglutide25$23,867
VraylarCariprazine Hcl13$21,825
JanuviaSitagliptin Phosphate16$13,822
JardianceEmpagliflozin14$11,201
VascepaIcosapent Ethyl11$5,830
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$5,569
SymbicortBudesonide/Formoterol Fumarate19$4,289
Humalog Kwikpen U-100Insulin Lispro13$4,059
CreonLipase/Protease/Amylase13$2,627
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$2,267
Levothyroxine Sodium234$1,840
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro11$1,767
Gabapentin103$1,384

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$41,32143 claims
Lilly USA, LLCTrulicity$79$29,34121 claims
AbbVieVraylar, Creon$489$24,45226 claims
Novo NordiskOzempic$335$23,86725 claims
MerckJanuvia$16,004$13,82216 claims
Boehringer IngelheimJardiance$13,397$11,20114 claims
AstraZenecaSymbicort$120,054$4,28919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Indian Land

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →